Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 "Fierce 15" most promising biotechnology companies. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。